• Are FDA’s response to serious criticisms of Reagan-Udall Foundation sufficient or appropriate?
• Are current US regulatory approaches injurious to, rather than protective of, public health?
• What is the role of science in driving FDA regulation and decisions on PMTAs?
• What are potential policy and regulatory solutions to the apparent contradictions in science and US/FDA approaches to harm reduction?
